ENTITY

Innovent Biologics Inc (1801 HK)

390

Analysis

Health Care • China

Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.

more

Refresh

Exchange Announcement • 20 Dec 2024 19:11

Voluntary Announcement - The National Medical Products Administration Approves Ros1 Inhibitor Dovbleron (Taletrectinib Adipate Capsule)

Exchange Announcement • 05 Dec 2024 22:43

Grant Of Share Options And Restricted Shares

Exchange Announcement • 03 Dec 2024 18:00

Voluntary Announcement - The National Medical Products Administration Granted Conditional Approval For Tyvyt (Sintilimab Injection) In Combination With Elunate (Fruquintinib) For The Treatment Of Advanced Endometrial Cancer

Exchange Announcement • 28 Nov 2024 12:00

Voluntary Announcement - First-Time Inclusion Of Sintbilo (Tafolecimab Injection) And New Indication For Olverembatinib In China'S National Reimbursement Drug List (2024 Version)

Exchange Announcement • 03 Nov 2024 19:55

Termination Of Connected Transaction

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x